ACADIA Pharmaceuticals Inc.

Ladies and gentlemen, thank you for standing by. My name is Krista and I will be your conference operator today. At this time, I would like to welcome everyone to Acadia Pharmaceuticals first quarter 2026 earnings conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question at that time, simply press star, then the number one on your telephone keypad. And if you'd like to withdraw your question, again, press star one. Thank you. I would now like to turn the conference over to Albert Kilgarny, Senior Vice President, Investor Relations and Corporate Development. Please go ahead.

Good afternoon, and thank you for joining us on today's call to discuss Acadia's first quarter 2026 financial results. Joining me on the call today from Acadia are Catherine Owen-Adams, our Chief Executive Officer, will provide some opening remarks, followed by Tom Garner, our Chief Commercial Officer, who will discuss our commercial brands, Debut and New Plaza. Also joining us today are Elizabeth Thompson, PhD, Executive Vice President, Head of Research and Development, who will provide an update on our pipeline programs, and Mark Schneier, our Chief Financial Officer, who will review the financial highlights. Catherine will then provide some closing remarks before we open up the call for your questions. We are using supplemental slides, which are available on our website, in the Events and Presentations section. On today's call, both GAAP and non-GAAP financial measures will be discussed, including non-GAAP New Plaza net sales and non-GAAP total revenues. The non-GAAP financial measures that are also referred to as adjusted financial measures pertain only to New Plaza sales in 2025 and their impact on total revenues. All references to non-GAAP are reconciled with the most directly comparable GAAP financial measures in our earnings press release and slide presentation, which has been posted on the investors page of the company's website. Before proceeding, I would like to remind you that during our call today, we will be making several forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements, including goals, expectations, plans, prospects, growth potential, timing of events, Future results and financial guidance are based on current information, assumptions, and expectations that are inherently subject to change and involve several risks and uncertainties that may cause results to differ materially. These factors and other risks associated with our business can be found in our filings made with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of today's date, and we assume no obligation to update or revise these forward-looking statements as circumstances change, except as required by law. I'll now turn the call over to Catherine for opening remarks.

Thank you, Al. Good afternoon, everyone, and thank you for joining us today to discuss our first quarter 2026 results. Acadia delivered a solid start to the year, with total revenue of $268 million in the first quarter, representing 11% year-over-year growth on an adjusted basis. Debut had an especially strong quarter, with sales of $101 million, up an impressive 20%, our highest year-over-year growth since the third quarter of 2024, marking an excellent start to the year. We are excited about the successful launch of Debut Sticks, with strong feedback from both caregivers and healthcare providers. As announced last month, Debut Sticks is now broadly available across the United States, and we're seeing strong early uptake from both new and previously discontinued patients that gives us confidence in our growth outlook. New Pleasured sales were $167 million in the first quarter, up 6% year-over-year on an adjusted basis. The first quarter performance reflects that some patients were slower to refill than in prior years. We are pleased to report that these refill dynamics have since normalized. Importantly, we saw double-digit referral growth in the first quarter and robust demand growth at 8%, even prior to the expected impact of the recent Salesforce expansion. I'm pleased to share that we are reaffirming our 2026 net sales guidance for both Debut and New Plaza. Looking at our pipeline, we have several significant catalysts on the horizon. Most notably, we are approaching the highly anticipated phase two readout for remnifanserin in Alzheimer's disease psychosis, which we continue to expect to share results from in the August to October timeframe. This represents a key inflection point for our company and could unlock substantial value given the significant unmet medical need in this indication. Additionally, the timing of our phase three study in Japan for tropinotide has accelerated. and we now expect results in the September to November timeframe of this year. I want to remind everyone of the tremendous opportunity we have across our pipeline. We have four molecules targeting large markets with a combined full peak sales potential of $11 billion, with approximately $4 billion of that specifically attributable to remnifantharone across the ADP and Lewy body dementia psychosis indications. This underscores the transformative potential of our research and development efforts. With that, I'll now turn the call over to Tom to provide a more detailed insight into our commercial performance.

Thank you, Catherine. Let me dive into the details of our first quarter performance. Starting with debut, I'm pleased to report another excellent quarter with revenue of $101 million, representing 20% year-over-year growth. This was another record quarter for unique patients receiving shipments, highlighting the continued momentum and durability of the debut franchise. Growth was fueled by robust referral volumes driven by new patient starts, alongside meaningful re-engagement of previously discontinued patients following the recent approval and launch of the new powder for oral solution formulation of Drafinitide debut sticks. During the first quarter, we launched debut sticks with a focus on sense of excellence to ensure optimal launch execution while gathering valuable real-world feedback. We've been extremely pleased with both the initial uptake and positive experiences we've received from both caregivers and healthcare providers. Through Q1, we received debut sticks prescriptions for more than 250 individual patients, demonstrating strong early demand for the new formulation. Notably, nearly 30% of these patients were either treatment naive or restarting therapy, aligning with our expectations and further supporting Debut's growth outlook. In addition, we're also seeing strong interest from existing patients in switching to the STIX formulation. Collectively, this early experience demonstrates how Debut STIX can help retain current patients, bring discontinued patients back into therapy, and grow the treated patient population, aligning closely with our long-term growth strategy for Debut. From a patient and caregiver perspective, Debut Stix offers meaningful advantages, including flexible dosing volume, potentially shorter dosing time, a preservative-free formulation, no requirement for refrigeration, and enhanced portability. These attributes are resonating strongly. with early feedback reinforcing the value of the new formulation, as you can see on this slide. Caregiver response has been particularly positive, with more than 80% of those who have tried STIX reporting high satisfaction, complemented by strong endorsement from health care providers across rep centers of excellence where the product was available through the first quarter. Following the FOCUS launch, we announced in early April that Debut STIX is now fully available in the US. We look forward to seeing the continued impact of this broader rollout for patients and caregivers. Outside of the U.S., our global named patient supply programs continue to contribute meaningfully to our growth through the first quarter. The number of patients receiving product through our MPS programs continues to increase over time, providing important access to patients. The recent Delphi expert consensus reinforces Debut's position as the standard of care for Rett syndrome. reflecting broad adoption across sense of excellence and accelerating uptake among clinicians treating RET patients. This important publication demonstrates that RET syndrome experts agree that debut plays a crucial role in patient care, including the importance of initiating treatment early and dosing individualized to the patient's needs. The Delphi publication adds to the growing body of real-world experience supporting debut. complementing our robust clinical trial programs that support the meaningful impact that Trifinatide can make for patients living with Rett syndrome. Taken together, the successful launch of Debut Stix combined with sustained referral strength and durable patient persistence positions Debut for continued growth through 2026 and beyond. Now turning to New Placid, which delivered sales of $167 million in the first quarter representing 6% growth year over year on an adjusted basis. I'd like to walk through the dynamics behind the quarter and explain why our confidence in full year performance remains strong. Starting at the top of the funnel, physician referral growth was strong at approximately 11% year over year, even ahead of the anticipated impact of our Salesforce expansion, which was completed in the quarter. This level of referral growth reflects continued physician confidence in New Placid, driving strong underlying demand. However, as Catherine noted, first quarter performance was impacted by a temporary increase in patients taking longer than expected to refill their prescriptions. This dynamic emerged in January and extended into early February, as refill timing lagged historical first quarter patterns. Importantly, these delays proved temporary. Patients who were late to fill returned in the latter part of the quarter, and we have now returned to normal patterns. Despite the short-term timing impact, New Plaza delivered 8% year-over-year demand growth in the quarter, reinforcing our confidence in the full-year outlook. As a reminder, our commercial strategy is focused on driving earlier awareness and use of New Plaza in the Parkinson's disease psychosis journey through smart, disciplined execution. We're sharpening prescriber reach, improving call quality, and maintaining tight segmentation, while strengthening field and digital engagement in order to engage physicians earlier and convert strong referral momentum into improved pull-through. Building on this foundation, we expect to realize the full impact of the recent 30% expansion of our customer-facing teams by late 2026 and into next year as we extend these capabilities across a broader target universe. In addition, we anticipate further benefits from our direct-to-consumer efforts. We've recently renewed our partnership with Ryan Reynolds for the unbranded More to Parkinson's campaign, reflecting its strong resonance with patients and caregivers, enabling us to introduce new content and creative to further raise awareness of Parkinson's disease psychosis. Since launching the campaign, awareness of hallucinations and delusions amongst the Parkinson's disease community has increased from 8% to over 30%, underscoring the campaign's significant impact. We're complementing this with refreshed branding created on NewPlasid.com to engage patients earlier in their journey and clearly reinforce NewPlasid as the only FDA-approved treatment for Parkinson's disease psychosis. I'd also like to highlight a significant milestone for NewPlasid. This year marks the 10-year anniversary of its FDA approval. Over the past decade, nearly 100,000 patients, along with their families and caregivers, have benefited from this therapy. This milestone underscores both the durability of the NewPlasid franchise and its meaningful impact on the Parkinson's disease community. In summary, NewPlasid remains firmly on track for another strong year, with continued referral momentum, the scaling impact of our expanded sales force, and ongoing market development supporting our path towards approximately $1 billion in annual sales by 2028. And with that, I'll now turn the call over to Liz to provide an update on our pipeline developments.

Thank you, Tom. Before turning to pipeline updates, I want to briefly address the retirement announcement we shared last week. For personal reasons, I've decided to retire by year-end. But while we seek the right next head of R&D, I remain fully engaged in driving our pipeline forward. We will ensure continuity through this transition, including supporting the upcoming Phase 2 readouts and early Phase 3 planning for remlifanserin. With that context, I'll now walk through the key R&D progress for the quarter. I'm pleased to share updates on our pipeline, which continues to offer meaningful opportunity with real momentum building across multiple programs. Across our eight disclosed programs, we continue to anticipate initiating five additional Phase 2 or Phase 3 studies by the end of 2027, demonstrating the breadth and depth of our development portfolio. Most recently, we successfully initiated our first in-human study of ACP271 in Healthy Volunteers, and I'm pleased to report that the study is going well to date. We continue to advance enrollment across several key studies, Our phase two study of ACP211 in major depressive disorder is progressing, as is our phase two study of remlifanserin in Lewy body dementia psychosis. And of course, both of these programs represent significant opportunities to address substantial unmet medical needs. Looking ahead, we currently anticipate reporting four phase two or phase three study readouts by the end of 2027. And of course, the closest to these is the top-line results from our Phase II study of remlifanserin in Alzheimer's disease psychosis. The Alzheimer's study is still unrolling, and the enrollment dynamics continue to support our expectation for top-line results in the August through October 2026 timeframe. As a reminder, throughout this study, we focused on ensuring our patient population has biomarker-confirmed Alzheimer's disease. which we think could be an important component of both technical and regulatory success. We're excited for this readout and what it could mean for the future of the company if successful. But most importantly, as a step towards relief for the patients and families affected by this challenging condition. Turning to regulatory and international developments, the terfenetide reexamination process in Europe remains ongoing. and we continue to expect that process to conclude by late June. We remain focused on working closely with European regulators to address their questions and support the positive benefit-risk profile of trofinetide for patients with Rett syndrome. In Japan, enrollment in our phase three trial with trofinetide has been progressing exceptionally well, and I'm pleased to share that we now anticipate completing enrollment this quarter. This accelerated timeline positions us for top line results in the September through November timeframe this year, which represents an earlier completion than we previously anticipated. Now, as a reminder, this is a small study that was designed with regulators to provide descriptive information on Japanese patients receiving trofinetide. We expect this study to provide the remaining new data needed for our Japanese filing package, which will rely largely on the Lavender trial to establish trofinetide's efficacy and safety. with an expected regulatory submission in 2027. These pipeline developments underscore our commitment to advancing innovative treatments across neurological and rare diseases, and we look forward to sharing more updates as these programs continue to progress. And with that, I'll turn the call over to Mark.

Thank you, Liz. I'll now walk you through our first quarter 2026 financial results. Starting with our revenue performance, Total revenue for the quarter was $268 million, up 11% compared to adjusted total revenue in the first quarter of 2025. New Plaza generated $167 million of net product sales in the first quarter, representing 6% growth year over year on an adjusted basis. As Tom discussed, we are very encouraged by the strong demand growth and referral growth in the quarter, which we saw even before the anticipated impact from the field force expansion that was completed in the quarter. The gross net adjustment for New Placid in the quarter was 22.1%. As stated in our press release, New Placid year-over-year growth metrics are derived by comparing our Q1 2026 GAAP New Placid net sales to our Q1 2025 non-GAAP New Placid adjusted net sales. Debut delivered strong performance with $101 million in net sales, up 20% year over year. Our debut results reflect the robust momentum Tom described in both the US market and through our international programs. The gross to net adjustment for debut in the quarter was 25.8%. Turning to our operating expenses, Research and development expenses were $76.9 million compared to $78.3 million in the first quarter of 2025. Our SG&A expenses were $171 million compared to $126.4 million in the first quarter of 2025, reflecting our continued investments in our commercial franchises with increased marketing investments for New Plaza and the expanded field footprint for both New Plaza and Debut, which both took place after the first quarter of 2025, which is an important consideration in any year-over-year comparison. Our cash position remains exceptionally strong with $851 million at the end of the first quarter as compared to $820 million at the end of the fourth quarter. This increase reflects our positive operating cash flow generation and positions us well to execute on our strategic priorities. Moving to guidance, I'm pleased to reaffirm our full year 2026 guidance for net sales and expenses. In terms of quarterly progression, we expect total revenue to be back-end loaded as the year progresses, with a greater sales contribution from both brands in the second half of the year, driven by the expected productivity ramp from our expanded New Plaza Field Force coupled with broader availability and adoption of debut sticks. With that financial overview, I'll turn the call back to Catherine for her closing remarks.

Thank you, Mark. As we wrap up today's call, I want to highlight the key milestones and catalysts that make 2026 such an exciting and potentially transformative year for Acadia. First and foremost, we're approaching our highly anticipated top-line results for remlifanthrin in Alzheimer's disease psychosis. which we expect to report in the August to October timeframe. This represents the most significant near-term catalyst for our company, with the potential to unlock tremendous value and address a massive unmet medical need affecting millions of patients and their families. The ADP market represents a substantial opportunity with no currently approved therapies, and successful results could position ramnifantharine as a cornerstone therapy in this underserved patient population. We also anticipate top-line results from our Japan Phase III trial with trofinetide later this year, which could establish an important new market for debut. This accelerated timeline reflects strong international engagement and our commitment to bringing innovative treatments to patients worldwide. Importantly, as we head into these upcoming data readouts, while Liz has announced her intention to retire at the end of the year, We are grateful that she will continue to lead R&D to provide continuity and leadership while we look to find a strong replacement. Beyond these clinical and regulatory milestones, we have a strong commercial foundation and we're pleased to reaffirm our 2026 financial guidance for total revenues of 1.22 to 1.28 billion. Furthermore, our cash balance of 851 million provides us with significant strategic flexibility enabling us to pursue business development opportunities, including potential acquisitions, licenses, and partnerships that could complement our existing portfolio and further accelerate our growth trajectory. We remain actively engaged in evaluating opportunities that align with our strategic focus on neurological and rare disease with significant unmet need. Throughout all of these initiatives, We remain steadfast in our mission to turn scientific promise into meaningful innovation for underserved communities. Every program in our pipeline, every commercial initiative we undertake, and every strategic decision we make is guided by our commitment to bring life-changing treatments to patients and families who need them most. The combination of our strong commercial performance, robust pipeline, and solid financial foundation positions Acadia exceptionally well for both near-term catalysts and long-term sustainable growth. We're excited about the opportunities ahead and look forward to sharing our progress with you throughout the year. And with that, we're happy to take your questions. Operator?

Thank you. If you would like to ask a question, please press star 1 on your telephone keypad to raise your hand and join the queue. And if you'd like to withdraw that question, again, press star one. Your first question comes from Tess Romero with JP Morgan. Please go ahead.

Hey, guys. Thanks so much for taking our question this afternoon. So, I wanted to ask a pipeline one here. So, where are you more precisely in terms of enrollment of the SAVES-2 Radiant Study of Replisanserin in Alzheimer's Disease Psychosis? And how confident are you in your timeline from August to October of this year? You know, when might you see the last patient in? And then second question is just, how is enrollment going in your Phase II Ong Mara study in Lewy Body Dementia Psychosis? And what is the right way to think about the potential timeline to data there as well? Thank you.

Thanks, Tess. I'm going to ask Liz to take us through the timeline.

Sure. Hi, Tess, and thanks for the question. So first off, for the ADP program, we continue to feel very good about that August to October timeframe. And the study is still enrolling, but we are getting to the last phases of enrollment. So we feel confident about that timeline. That said, I'm not yet able to narrow that any further than what we have right now. As we look at Lewy Body, I'm pleased with the enrollment progress that we have there. I don't think we've yet shared publicly what our expectations around the end are. We wanted to get a ways into enrollment. So I do look forward to sharing more about that in future. But so far, pleased and on track with what I was hoping for. Thanks, Jess.

Your next question comes from the line of Ash Verma with UBS. Please go ahead.

Hey, thanks for taking our questions. So maybe just on this upcoming phase two study, I know you mentioned the biomarker-based selection for confirmation of the Alzheimer's patients as opposed to just looking at the clinical presentation. Can you help us explain a little bit Why is that critical for clinical trial execution? And just in the real-world setting, I know patients are typically not diagnosed based on the clinical presentation and imaging. They are diagnosed based on clinical presentation and imaging and not necessarily biomarker confirmation. So how does that inform the applicability of the results to real-world? And then secondly, just on ACP204, so Aminoplacid has a black box warning for this increased mortality in elderly patients, you know, given that this is kind of a connection of that, would the molecule still port the black box warning if it comes to the market? Next.

All right. Thanks, Ash. Some comprehensive questions there for Liz to get to. So let's start at the top and go down.

There was a lot in there. I was madly writing down. So hopefully I captured everything. So in terms of the biomarker basis, I think this has been a really interesting thing to watch in the Alzheimer's field with, you know, a number of years back, there was the idea of biomarkers being part of a clinical trial basis way of thinking about diagnosis. And at this point, it actually is considered part of the diagnostic pathway for Alzheimer's. I fully anticipate by the time we would make it to FDA with our potential package for remlifanserin that there would be an expectation that Alzheimer's disease is a biologically confirmed disease. And so we've put this in place to try to future-proof the program that we have. And I think that probably touches a little bit on your point about real world. I think that the real world is starting to move that way as well. So we think that this has an important component of regulatory success. I should note, it may also have a potential opportunity for improving technical success. There is a possibility that this helps you be more confident that the patient population you have is truly Alzheimer's and that there's less heterogeneity in that patient population from a response perspective. So we think it's important on both aspects. Finally, to your point about the black box warning, it's a really great question. There was an FDA Duke Margolis workshop, oh jeepers, probably about a year and a half ago at this point, and one of the discussion points was about the black box warning and for future agents, what kind of data might be necessary to help FDA make data-based decisions on individual agents. So we attended that eagerly, learned from it, and have taken into account feedback that we got both through there and through other discussions about the kind of information we need to collect to be able to let FDA make a specific decision on remolfanserin and whether it does or does not warrant such a box warning. So right now I don't know, but... We know the data we need to collect, and we do think that there is good reason to think that this could be a path forward without a black box, but it's going to depend on the data at the end of the day.

Thanks, Liz. Thanks, Ash.

Your next question comes from the line of Ritu Baral with TD Cowan. Please go ahead.

Hi, guys. Thanks for taking the question. I've got some more REMLIS answering questions as well, extending from clinical into commercial. One, as we think about that Phase II data that's coming, what should our expectations around either effect size or delta on the SAPs HDB? Is there an accepted minimal clinically important difference here? And what, you know, what frames success on a statistical level? And then as we look at our market model, just given the recent competitive approval of Alzheimer's, of an Alzheimer's agitation drug, how should we be thinking about differential diagnosis between the two indications, accurate diagnosis, and sort of

decision treatment decisions um between the two phase with all the interest in reveler fans around so i'll ask liz to kick that off and then maybe listen tom can both talk to the market a little bit as well yeah absolutely so in general terms of what we should all be looking for and and what defines phase two success for us as we were walking into this um this uh readout There are a few things that I'm looking for. I mean, the main thing really with any phase two is what you're looking for is phase three enabling data. You're looking for information that helps you know what to do in a phase three, any modifications you may need to make, et cetera. Beyond that, I'll be looking for continued information that suggests that this, that Remlis-Ansarin is delivering results that are consistent with our TPP, You know, we're not going to know all of those definitively coming out of phase two, and there will be some things that we already feel pretty good about, but I'll be looking. You know, we want to make sure that we've got something that can be dosed once a day, that can be done easily with respect to con meds, with respect to food, anything that makes it easy for patients to take their drug. We are, of course, looking for efficacy. We'll be pleased with an effect size that's in line of what we're powered for, which is a 0.4 or a moderate effect size. We'd be pleased with safety that looks similar to the PIM of answer and profile. And this part, of course, we definitely won't be able to definitively answer out of phase two, but continue data that suggests that there's no deleterious impact on movement, on cognition, which from the overall PIM of answer and data set, we do feel good about. And hopefully we'll get some directional sense there. To the question about MCID on SAPS HND. There's not a well-established one at this point. Part of what we would be doing for a dossier that would go into FDA eventually is establishing that MCID based in part on the Phase II data that we have. We are, however, also looking at, in addition to just the Delta, some responder levels, those who have improved by at least 30%, those who have improved by at least 50%, which we think help contextualize the meaningfulness of those results. And then I think there was also a question about the recent Axome approval and agitation. I'll just briefly say, you know, we're always happy to see more options for patients. Alzheimer's disease is a complex disease with many manifestations that are really profoundly impactful for patients and their families. What I think is important to keep in mind is that we always did envision, as we looked at our business opportunity for remlifanthrin, that there is a potential competition, particularly including agents that would be approved for agitation, and that there are distinctions between agitation and psychosis. Agitation is complex. There are a lot of things that can play into it. It can stem from pain. It can stem from cognitive challenges, and it can stem from psychosis. For remlifanthrin, we are... there is some PIM of answer and data suggesting that in those patients who have significant agitation and significant psychosis, if their psychosis improved, it did seem to suggest that their agitation improved as well. So there may be an aspect of agitation, but I wouldn't expect that we would have impact on pain, pain-induced agitation, et cetera. And sort of on the flip side, if you look at molecules that are effective in agitation, There's not necessarily a good reason to believe that they'll be impactful on any of the things that are actually driving that agitation like psychosis. I mean, actually, if you look at various components, they actually can be associated with an increase in psychosis. So taken together, I think we think that there's ample room for multiple players in this space and that effective players in agitation are going to be meaningfully impactful for the opportunity you see with Rymel's answer.

I think Liz has covered that brilliantly. I'm going to breathe now.

And I'll throw the next question. Your next question comes from the line of Yigal Nachumovitz with Citigroup. Please go ahead.

Hi, this is Caroline DePaul. I'm for Yigal. Thanks for taking our question. So, you know, switching years to baby sticks, you disclosed that 30% of patients are either treatment naive or returning after previously discontinuing the liquid formulation. Just wondering how this compares to your expectations for the launch, and do you still expect to capture 400 or over 400 incremental patients with sticks? And if so, what is the anticipated cadence for capturing those patients? Thanks.

Perfect. Thanks for the question, Carolyn. So let me provide some additional color on your question just regarding kind of our expectations and performance through the first quarter. So just as a reminder, you know, our launch strategy was very focused on COEs through the first quarter. So we've not yet gone broadly into the community. However, we have been very, very pleased with the initial uptake that we've seen. So the 250 patients But the 250 prescriptions that we had, we actually shipped 220 of those in the quarter, which, again, I think just talks to the fact that we're able to get this drug into patients' hands quickly. In terms of how it's doing versus expectations, we would actually say that the ramp in terms of speed that we're seeing here is actually going quicker than we anticipated. I mean, I think the 450 that you referenced is what we had spoken about at JPM. We still think that that holds true. And we had modeled that over a three-year period, which would basically get us to sticks being the dominant skew by the end of that time. I think we may end up in a situation where it goes slightly quicker than that. But again, I think the 30% that we're seeing is broadly in line with our expectations. And we're encouraged by the fact that it's not only returning patients, but naive patients as well. supplemented by the fact that we're also seeing significant interest from patients already receiving the liquid formulation. So I think taken together, it gives us real optimism for the future of debut more broadly and the role that sticks can really play in fueling that growth.

Thanks, Caroline. Your next question comes from the line of Brian Abrahams with RBC Capital Markets. Please go ahead.

Hey, guys. Good afternoon. Thanks for taking my question. Maybe going back to Remli, as we think about Remli and what could generate success in the upcoming study, I guess can you, what exactly are the key differences on potency, saturation, and receptor binding properties that you might expect from 60 milligrams of Remli as compared to the marketed and previously tested dose of Pimivanserin? Or should we think about this more as being just having a more homogenous population and a study design that leverages prior learnings and uses a more sensitive endpoint? Thanks.

That's a great question, and I think we can think of it as potentially a little bit of both. You know, what we do know from our prior Pimavanserin work is that if you look over the exposure response range, there does seem to be a suggestion that at exposures that are higher than what you can get to with the currently marketed dose of Pimavanserin, you are able to get greater efficacy. So there is at least a good reason to think that if we're able to push to higher exposures, as we are with the 60 milligram dose, we may be able to get further up on that exposure response curve. That said, even if that doesn't play out exactly the way that we're expecting it to, I do think that having a study design that is really specifically focused in on the Alzheimer's population, I think that's first and foremost our learning from regulatory in times past, is that they're going to need data that are specific to that population, which as I mentioned before on this call, we're going the extra step in biomarker confirming. That's going to be important. And we think that it's going to be, you know, we've done other modifications of things like trying to make sure that we have a slightly more severe baseline population in terms of their psychosis based on PIM data that suggested you get better responses there, as well as the fact that we're looking at endpoints that we think, you know, SAPS H&D, as well as other things that we have in our study like the NPIC, that we think may be better suited to being able to distinguish differences than the NTiNH that we used way back in the day in our Phase II trial. So, I think it's a little bit of all of the above. Thanks, Liz, and thanks for the question.

Your next question comes from the line of Kendine Ahmed with Bank of America. Please go ahead.

Okay. Thank you for taking my question. How are you thinking about the read-through from the Phase II study for Alzheimer's onto the Lewy body study itself? Going back to a few years ago when a similar study was done, Pima did seem to show a pretty strong signal there. So regardless of how it turns out for Phase II for Alzheimer's, how should we be thinking about the de-risking for Lewy body for next year? Thanks.

Love that question and love what's baked into it. I agree that, you know, while it's in small numbers of patients, I've always found the data in Pimivantrin and Lewy body to be fairly striking. In the Harmony study, just for people who are a little less familiar than you are, the withdrawal study, there were about 20 patients per arm with Lewy body. And of those who had their treatment withdrawn, about 55% of them relapsed. And those who continued on, only about 5% did. So striking while in a small number of patients. So that actually, to your point, regardless of how the ADP study turns out, and we do have high hopes for that based on all the things that I just talked through in the last few answers, but regardless, I think we remain very optimistic about the Lewy body study. I think the one thing that could be a read-through would be something significant from a safety perspective. I'm not currently anticipating that, but obviously we only know that when we get the data at the end of it. Thus far, though... You know, we're optimistic about Alzheimer's, but regardless of that, I think we're very optimistic about Lewy body.

Do you want to talk a little bit about how we think the formulation of Ramli might suit the Lewy body patient as well in terms of their fragility and the dose?

So we do think that, you know, obviously the Lewy body patient population, both of these patient populations obviously are complex and with significant needs. Lewy body, generally speaking, is, I think, accepted to be a little bit more frail, and we think it is even more important to have something that is very safe and something that is very easy to take, which, again, has been something we've really prioritized with Rundle Sancerin.

Thanks, Liz. We're looking forward to seeing you next week, Suzanne.

Your next question comes from the line of Mark Goodman with Lear Inc. Please go ahead.

Yeah, my question is on New Placid. And if we had a delay in patients that you know are kind of getting on therapy, but they were delayed from January and part of February, why would we not have a great second quarter that kind of makes up for that low first quarter? Because your guidance is kind of all this back-end loaded discussion. So I think you understand the question. Thank you.

Yes, so let me kind of address that initially. I think we are expecting a strong second quarter mark. The dynamics that Tom referred to are definitely showing that from the current sales force. When we talk about the back end of the year, it's really the impact of the additional expansion. But let me just hand it over to Tom to sort of talk you through those specific things.

Absolutely. So thanks for the question, Mark. So as a reminder, we executed the 30% expansion of our sales team in Q1. That team has been in the field for now around kind of six weeks by the time we got to the end of the quarter. So we're really not seeing the full quarter impact of the productivity ramp that we anticipate seeing. You are correct. We saw a very nice increase in referral volumes, 11% year over year. We saw good demand growth. But, you know, we did have this issue just in terms of late returning patients through the quarter, which was, you know, kind of further impacted by the normal Q1 dynamics you would expect to see for a Medicare population. So moving forward, you know, we anticipate that the productivity ramp will continue to impact us moving into the second quarter and beyond. We're continuing to push on the DTC efforts that I mentioned, both in terms of our unbranded, more to Parkinson's and branded efforts. And in addition to that, you know, all of the additional work that we're putting into place just around the expanded target universe that we're now going after, as a reminder, we've now increased to a target universe of just over 10,000 HCPs. We believe that tackling that is going to lead to significant uptick for the brand more broadly because we still have, you know, plenty of share growth that we can continue to drive over the coming quarters. In terms of the question just...

The one thing I'd add, thanks for that, Tom, just from a financial perspective, it's more late to refill of existing patients, not new patients. So those patients that were late to refill essentially missed a script in the year, so it's kind of a lost revenue. The good thing, though, is it's not a lost patient. Those patients have come back based upon our historical numbers and have refilled in the quarter. So the positions are strong going forward, but not necessarily just a rebound of recouping what was missed in January and early February.

Your next question comes from the line of Jack Allen with Baird. Please go ahead.

Great. Thanks so much for taking the questions, and congrats on the progress. Just two quick ones from us on REMLOT. in the ADP study. This is a placebo-controlled study, and the FDA has started to put out a lot of guidance around potentially allowing for filings on single trials. I just wanted to hear any thoughts you had on the potential to file on positive results in a placebo-controlled setting for REMLA. And then, briefly, on Dayview, it seems like you're making a lot of progress with the STIX formulation, and you have thrown out the $700 million in aspirational sales number for 2027 longer-term guidance there. I'm curious to what extent you factor in gene therapy in RET into that longer-term guidance as well.

Do you want to kick us off, Les?

Sure. So, great question about the single trial, and obviously we've had lots of discussions about this. What I'd say is, you know, thus far I think we're all still waiting for a guidance document around this to have a better understanding of the thought process. It's not clear some of the things which I anticipate will likely still apply, things like the size of the safety database. And those are the types of considerations that make it such that my current expectation is that our base case assumption, which is that we need our phase two and we need two phase threes, is going to be what we're going to need at the end of the day. I do want to note that, obviously, if we were to see really striking results in this trial, We certainly would go have a conversation with FDA to explore what possibilities exist. But right now, again, our base case assumption is that we are going to need more than this single study just purely based on the size of exposure that we would have.

And just a top-line basis, I think we continue to be very confident in our $700 billion guidance for 2028. We have

of course thought about competitive dynamics through that period including gene therapy uh tom do you want to add anything else that the team's been thinking through yeah absolutely so again very pleased with the initial progress that we've seen the sticks obviously this is complementing what we've already been driving over the last year with liquid as well as we continue to expand into the community i think it's worth reminding everyone that you know our penetration for debut across the coes and um Community Physicians is still in the 40% mark. So we've still got significant headroom for growth for this brand. And we believe with STIX, we can capture both naive and restart patients who may have stopped. And as a reminder, we have around 1,000 patients who have tried Debu but are no longer continuing treatment. We believe that we're going to be able to re-engage those. And we've already seen that through the first quarter. As it relates to gene therapy, as we mentioned on the call, we've also been very pleased to see the Delphi consensus published, which clearly positions debut as standard of care for patients living with Rett syndrome. Um, our view is that, you know, I think it will be good news to have more treatments available for the Rett disease for the Rett syndrome population. Um, I think we have to wait and see what the data actually tells us as the gene therapies come to forum. We're going to be interested to see how that plays out, but irrespective, we believe that debut will have a role to play. across all of these patients moving forward, whether gene therapies exist or not. So again, as Catherine said, we feel really good about the 700 million that we've stated by 2028.

Your next question comes from the line of Amy Fadia with Needham. Please go ahead.

Hi, good afternoon. Thanks for taking my question. And my question is on . With regards to the powering of the study, I think you mentioned that you're looking for a 0.4 point change. What is the minimum effect size you need to see for the study to be statistically significant? And then, as we also are expecting data from CoBEN-FE to be adapted to study, you know, where they'll be looking at the endpoint of NPIC, when you give us the top-line data readout, would you be providing NPIC data? And at what time point is that being measured? Just trying to get a sense of, you know, how will we compare data across trials just to sort of understand the competitive profile of this product when the data runs out. Thank you.

Well, I always feel like I need to start with a, you know, you need to be careful in cross-study comparisons. But in seriousness in this case, you know, I think an important thing that I should note is that NPIC was an addition to our study after it had gotten started. It was actually one of the earlier things that I did in my tenure here. And accordingly, we will not have NPIC data on all patients who are participating in the Alzheimer's study. So we think that this is going to be important in the phase two Alzheimer's study, sorry, I should be clear there. We think this is going to be important information, but I don't know that I would anticipate it would be, for example, part of a top-line result. It is an exploratory endpoint with a subset of patients. In terms of powering expectations, so we are powered at 80% for an effect size of 0.4. So you can imagine there's a little bit of flex around that with scenarios that could still be statistically significant, but that's generally what we're looking for.

Thanks, Ami.

Your next question comes from the line of Shawn Lamann with Morgan Stanley.

Please go ahead. Hi, good afternoon. This is Catherine on for Shawn. Thank you so much for taking our question. We had another one on debut six. As adoption scales, can you just provide some color if you expect any meaningful change in persistency versus the liquid formulation, or is the primary benefit improved front-end initiation of reduced early friction? And just as a quick follow-up, I think you mentioned about 1,000 patients have previously tried DEBU. Can you share more about your strategy to re-engage these patients? Thanks so much.

Absolutely. So let me take that for you, Katherine. So starting with persistency, what I would say is, you know, we're monitoring this very, very closely because, as you would imagine, if we can improve persistency further, over and above what we're seeing with liquid, you know, obviously that would be very advantageous for us. Just as a reminder in terms of the latest data that we have, just regarding persistency with the liquid formulation, at 12 months, we are now north of 55% remaining on treatment through 12 months. And we're retaining about 50% of patients through 18 months. So persistency for liquid actually continues to improve over time. And the latest data we have is that 74% of our active patients have actually been on treatment for 12 months or longer. So, you know, we continue to be pleased with just the growing group of like persistent, uh, persistent patients who are continuing to see benefits with debut sticks. Um, to your question, we believe it can help in terms of initial friction. Obviously there is some significant advantages that we believe exist that go beyond the liquid formulation. But as it stands at the moment, it's probably too early to be definitive as to how STIX will perform in the real world in comparison to Liquid, but we will be sharing more detail in due course.

Do you want to talk to the 1,000 patients on how many of those we think might be up for grabs?

Yeah, absolutely. So as you think about the 450 patients that we spoke about earlier on in the year, and you kind of break that down, we think that roughly three-quarters of those would be naive to treatment, and the remaining quarter would be restarts. If you look at what we're seeing so far through Q1, it's roughly a 50-50 split of that 30%. We're seeing both naive. We're also seeing returning patients. But as I mentioned on the call, we're also seeing significant interest from existing patients receiving the liquid formulation in switching to STIX. So taken together, that's where we are. And just to close this one out, the momentum that we saw in Q1 actually has continued into Q2 as we've gone broader into the community. So again, excited to share more details in due course, but we're very pleased with the initial uptake of STIX.

I think Q2 will be a much more descriptive story about STICs and the types of patients we're seeing. So, we look forward to sharing more then. Catherine, thanks for the question.

Your next question comes from the line of Evan Segerman with BMO. Please go ahead.

Hi. I'm Malcolm Hoffman. I'll go for Evan. Thanks for taking our question. Asking about STICs again, just wanted to see if there was any specific stocking for STICs formulation this quarter. And then also, I want to get a sense of how you can ensure patients proceed with refills for the sixth formulation to kind of continue the strong momentum we've seen in this quarter. Appreciate it.

Perfect. Yes, happy to take that, Malcolm. So first question in terms of stocking, what I would say is very similarly to what we see with liquid. You know, we supply everything through a single specialty pharmacy, and it really is on a patient-by-patient basis. So there is very limited stocking that we anticipate seeing or have seen. And then in terms of refills, as I mentioned, of the 250 prescriptions that we actually had in the quarter, over 220 were actually filled. So we're not seeing any issues as it relates to payers or formulary issues on the whole. We're actually seeing it seems to be very smooth and in line with our expectations, which again is a nice group point that the strategy that we've employed here in terms of a limited launch has worked well for us.

That's Malcolm.

Your next question comes from the line of Rudy Lee with Wolf Research. Please go ahead.

Hey, thanks for taking my question. Just a quick follow-up for LDP trial. So how would these two endpoints being measured in the ADP trial help inform the benefits in LBDP, which is measuring a different endpoint of SAP's LBDP? And to what extent do their components overlap? Thanks.

I think it was a little bit difficult to hear some of that, Rudy, but I think it was to do with the different measurements of endpoints in ADP and LBD and Tau versus maybe the alpha-synuclein view of biomarkers.

Okay. Thank you. Thank you. I missed a bit of it. Appreciate it. So, first off, I guess a couple of important things with respect to the biomarker considerations. There are a number of more established biomarkers at this point that are considered to support the Alzheimer's diagnosis, and so we are actually requiring a biomarker confirmation of the diagnosis for entry into Alzheimer's. The Lewy body field is in a much more exploratory phase, and so we are including an assessment of alpha-synuclein but it's not a requirement to get into the trial. It's a thing that we think is going to help inform us in terms of potential future trial design and also hopefully contributing to the science. In terms of the endpoints, there is a fair amount of overlap between the SAPS HMD and the SAPS Lewy body. They are both derived from the overall SAPS scale and are a similar but not exactly the same subset of attributes. The SAPS-Louis body in particular was based on those aspects that we saw in the PDP and the PIMA Bancer and PDP trial that seemed to be most impacted. So that was the driver beyond that, but a lot of overlap between those two endpoints.

Thanks, Rudy. Your next question comes from the line of David Huang with Deutsche Bank. Please go ahead.

Hey, this is Sam on for David. Thanks for taking the question back to debut. Is there anything else that you're able to share on the prescribing penetration dynamics in the quarter as it relates to community setting versus centers of excellence? And as a follow up, noting that the sticks formulation was initially launched in centers of excellence. How should we be thinking about the impact of that formulation in terms of how you think would resonate and drive prescribing in the community? through the rest of the year in the future.

Thanks. Absolutely. So I have to say that question, Sam. So as you would imagine, given our strategy for debut six was really focused on COEs at launch, we did actually see an increase in terms of the number of or the overall volume of prescriptions that was coming from COEs in the quarter. So I think we were roughly 79% was coming from the community in the quarter.

From the COE.

From the COE versus a lower number from the community. And I think, again, that's just reflected in the fact that there's been this significant excitement amongst the community around STICs. Um, as you think about kind of the penetration that we have, which again, we've spoken about in the past, we still have significant opportunities. So our penetration within. Even with sticks is around 60% penetration in the community currently sits around 28% before the launch of sticks. Um, of note, you know, both of those have grown significantly over the last year. Most importantly though, our penetration within the community, which is a reminder is about 65% of the overall available volume. has grown by about 7% on an actual basis over the last year. So again, I think a nice proof point that the strategy that we've employed to kind of focus on COEs but expand our reach into the community and STIX is very much going to be a part of our strategic roadmap there is working for us. And that's what's giving us real confidence in the outlook for debut for this year and moving forward.

Thanks, Sam. You're next. Your next question comes from the line of Yatin Suniha with Guggenheim. Please go ahead.

Hey, guys. Thank you for taking my question. Just a quick one on the reexamination process happening in Europe. Could you just talk about where you are? What do you expect to learn from the process there on phenotype? Thank you.

So the reexamination process, there are a few points along the way. There is your original intent to request reexamination. We did that very shortly upon receiving the original negative opinion. There's submission for, there's assignment of new rapporteurs, which has occurred. There is, excuse me, my voice is going today. There is submission of the grounds for reexamination, which we have completed. we anticipate an upcoming SAG meeting and then there may or may not be an oral examination meeting. So we are just past the submission of our grounds for reexamination. Thanks, Liz.

Your next question comes from the line of Paul Matisse with Stiefel. Please go ahead.

Hello, this is Julian on for Paul. Thanks very much for taking our questions. Really quickly on DD, just curious if if anything has changed and, um, you know, how you may be prioritizing, um, you know, external innovation versus internal, um, especially with the announcement, uh, disclosed, uh, last week, um, elsewhere. Also just curious on, um, do you plan on disclosing a total number of shipments at all moving forward? I know it's something that, that you disclosed in 4Q, and I know you said there was a record number this year, but just wanted clarification on that. Thank you.

I'll give the team a rest from answering, give Liz's voice a rest, and tackle both of those. So in terms of BD, you know, as we've stated, we remain very active and focused on our BD strategy. As you pointed out, we do have a very rich internal pipeline, and our late stage is certainly looking great in the next two years, but obviously we're managing this for the longer term, we're really focused on kind of two areas really right now. One is later stage assets that we could bolt onto our current commercial franchise, which Tom is leading with such great success. And so we're looking there, but we're also looking at continuing to refresh our early stage pipeline, which Liz and her team are managing. So those kind of are two main areas of focus right now. We have a lot of ability to flex with our balance sheet and we know that it's a very compassionate process. We are actively involved in processes and we continue to look for the right fit for Acadia. We're not under any particular pressure right now, but we are looking for strong fits for our business moving forward to drive that long-term value and growth for our shareholders, but also more importantly, the patients that we aim to serve. In terms of the shipping, we did commit to kind of moving now towards the financial dollar top line. We feel after three years of launch that sort of specific patient level metrics on shipping for debut is probably not the right way to assess the brand. We will continue to give clarity like Tom has today on the sticks dynamics. You can see that playing forward, but in terms of patient shipped, we're not going to be sharing that anymore, but it just does continue to grow. And we're very confident again in our full year forecast for both brands. And thank you for the question.

Ladies and gentlemen, that does conclude our question and answer session, and I would now like to turn the conference back over to Catherine Owen-Adams for closing comments.

Just like to thank everybody for their great questions today and the team here for answering them, and specifically Liz for all the great answers on remlifanserin. We're very excited about the next few quarters for Acadia, both with our commercial brands, but also obviously the top line results of remlifanserin. And we look forward to continuing to discussing with you and to our conferences in the next coming weeks. Thanks again for your interest in Acadia today.

Ladies and gentlemen, this does conclude today's conference call. Thank you for your participation and you may now disconnect.